Overview

This trial is active, not recruiting.

Condition acetaminophen toxicity
Sponsor Arkansas Children's Hospital Research Institute
Collaborator University of Arkansas
Start date August 2011
End date December 2015
Trial size 120 participants
Trial identifier NCT01575847, Acetaminophen Adduct Dipstick

Summary

This study is a non-intervention, clinical study to test "research use only" APAP protein adducts dipsticks in human blood samples. The study will be conducted in two phases. In phase 1, the research use only dipsticks and dipstick testing components will be tested for feasibility in the emergency department at UAMS. Patients will be enrolled that are having an acetaminophen level obtained as part of their medical evaluation. In phase 2, the research use only dipsticks will be tested in centers that participate in the Acute Liver Failure Study Group (ALFSG), a clinical research network funded by the National Institutes of Diabetes, Digestive and Kidney Diseases (NIDDK). Subjects participating in the clinical registry of the ALFSG will be approached for enrollment. These patients all have the diagnosis of acute liver failure or acute liver injury from a variety of etiologies, including APAP. A single blood sample will be obtained and will be aliquoted for 1) testing by the dipstick and 2) testing by high performance liquid chromatography with electrochemical detection (HPLC-EC) analysis for APAP protein adducts. APAP levels will also be determined from the second aliquot of blood. In both Phase 1 and Phase 2, the dipsticks will be read manually and by dipstick readers by independent testers that are not directly involved in the clinical care of the patients. The results of the two dipstick readings will be recorded, will remain confidential and will not be used in the diagnosis or management of the patient. The results of the dipsticks and HPLC-EC assays will be compared to the final patient diagnoses.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective
Arm
Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation. Part 1 20 subjects Part I Inclusion Criteria: Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management. Exclusion Criteria: Previous recent history of APAP overdose in the previous 30 days.
Part 2 Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making. Part 2 100 subjects Part 2 Inclusion Criteria: Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry. Exclusion Criteria:

Primary Outcomes

Measure
Accuracy of dipstick compared to HPLC-EC Method for detecting assays
time frame: Each subject will have one sample taken but chart review could last entire hospitalization expected average of 2 weeks

Eligibility Criteria

Male or female participants at least 12 years old.

Part 1 Inclusion Criteria: - Subject is 12-18 years of age. - Subject has an APAP level ordered as part of clinical management. Exclusion Criteria: - Previous recent history of APAP overdose in the previous 30 days. Part 2 Inclusion Criteria: - Subject is 18 years of age or older. - Subject is enrolled in the ALFSG registry.

Additional Information

Official title Adduct Dipstick for Diagnosis of Acetaminophen Toxicity
Principal investigator Henry Farrar, MD
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Arkansas Children's Hospital Research Institute.